Skip to content
Bored Studies
RecruitingPhase 2

A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Kymera Therapeutics, Inc. · NCT07677059

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
264
US sites recruiting
3
Study start
June 25, 2026
Record last updated
October 7, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This Phase 2b open-label, long-term extension study is designed to evaluate the long-term safety and efficacy of KT-621 in participants with asthma who were previously enrolled in the parent study (KT621-AS-202) of KT-621 for asthma. The main goals of this study are to investigate the long-term safety and tolerability of KT-621, the long-term efficacy of KT-621 at treating asthma, and how KT-621 behaves in the body long-term.

Being studied: KT-621

Conditions: Asthma (Diagnosis)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Must have completed all visits of the parent study, per its protocol, up to the end of treatment (EoT) visit.
  • Must be willing and able to comply with scheduled visits, treatment plan, laboratory tests, other study-related procedures, and questionnaires, including completing the electronic diary (e-diary), for the duration of the study as required by the study protocol.
  • Must agree to contraceptive requirements in compliance with the clinical study and local requirements.

Exclusion Criteria

  • Must not have experienced any clinically significant change in health status during the parent study, which, in the opinion of the Investigator, would interfere with participant safety, study evaluations, or compliance with study procedures; or otherwise make the participant unsuitable for participation in this study.
  • Must not have developed an AE during the parent study, that in the opinion of the Investigator or of the Sponsor's Medical Monitor, could indicate that continued treatment may present an unreasonable risk for the participant.
  • Must not have met permanent discontinuation criteria and/or permanently discontinued study treatment for any reason during the parent study.
  • Must not be a member of the Sponsor or site's investigational team or their immediate family.
  • Must not be unsuitable to enter the study for any other reason, as judged by the Investigator, including potential risk of noncompliance to study procedures.

Recruiting US locations

Study contacts (from the official record)

  • Kymera Medical Director · 857-285-5300 · clinicaltrials@kymeratx.com
A Long-term Study of KT-621 Administered Orally to Participants… (NCT07677059) | Bored Studies